We're Not in Kansas Anymore, Toto: Product Liability Biologics and Biosimilars
Biologic therapeutic products are a current focus of industry and government action. Biologics are used to treat a wide variety of diseases, including cancer and immune disorders, and represent a large and fast-growing segment of health care therapies. On March 23, 2010, Congress passed the Biologics Price Competition and Innovation Act (BPCIA) that established an abbreviated pathway for FDA approval of "biosimilar" products, often thought of as the "generic" form of biologic products. In a cutting-edge article published in For the Defense, Bridget Ahmann, Jennifer Dukart, Denise Kettelberger, and Joe Price forecast the potential product liability implications of the BPCIA and its proposed regulations. Their analysis will serve as a guide to biologics companies resisting attempts by plaintiffs to litigate in this novel arena.
The material contained in this communication is informational, general in nature and does not constitute legal advice. The material contained in this communication should not be relied upon or used without consulting a lawyer to consider your specific circumstances. This communication was published on the date specified and may not include any changes in the topics, laws, rules or regulations covered. Receipt of this communication does not establish an attorney-client relationship. In some jurisdictions, this communication may be considered attorney advertising.